EP1280409A4 - A GENTHERAPY SYSTEM AND METHOD USING ALPHA-MSH AND ITS DERIVATIVES - Google Patents

A GENTHERAPY SYSTEM AND METHOD USING ALPHA-MSH AND ITS DERIVATIVES

Info

Publication number
EP1280409A4
EP1280409A4 EP01930932A EP01930932A EP1280409A4 EP 1280409 A4 EP1280409 A4 EP 1280409A4 EP 01930932 A EP01930932 A EP 01930932A EP 01930932 A EP01930932 A EP 01930932A EP 1280409 A4 EP1280409 A4 EP 1280409A4
Authority
EP
European Patent Office
Prior art keywords
msh
alpha
derivatives
gene therapy
therapy system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01930932A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1280409A1 (en
Inventor
James M Lipton
Anna P Catania
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zengen Inc
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Publication of EP1280409A1 publication Critical patent/EP1280409A1/en
Publication of EP1280409A4 publication Critical patent/EP1280409A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
EP01930932A 2000-04-28 2001-04-27 A GENTHERAPY SYSTEM AND METHOD USING ALPHA-MSH AND ITS DERIVATIVES Withdrawn EP1280409A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20028700P 2000-04-28 2000-04-28
US200287P 2000-04-28
PCT/US2001/013826 WO2001082699A1 (en) 2000-04-28 2001-04-27 A gene therapy system and method using alpha-msh and its derivatives

Publications (2)

Publication Number Publication Date
EP1280409A1 EP1280409A1 (en) 2003-02-05
EP1280409A4 true EP1280409A4 (en) 2004-05-19

Family

ID=22741073

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01930932A Withdrawn EP1280409A4 (en) 2000-04-28 2001-04-27 A GENTHERAPY SYSTEM AND METHOD USING ALPHA-MSH AND ITS DERIVATIVES

Country Status (6)

Country Link
EP (1) EP1280409A4 (ja)
JP (1) JP2004509065A (ja)
CN (1) CN1429073A (ja)
AU (1) AU2001257420A1 (ja)
CA (1) CA2406755A1 (ja)
WO (1) WO2001082699A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106905432B (zh) * 2015-12-18 2018-12-21 兰州大学 一种α促黑素细胞激素的融合蛋白及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033658A1 (en) * 1998-12-09 2000-06-15 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2000042856A1 (en) * 1999-01-22 2000-07-27 The Schepens Eye Research Institute, Inc. Activation of regulatory t cells by alpha-melanocyte stimulating hormone
WO2002006316A2 (en) * 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532347A (en) * 1992-04-10 1996-07-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization DNA encoding α melanocyte stimulating hormone receptor
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
ATE348155T1 (de) * 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033658A1 (en) * 1998-12-09 2000-06-15 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2000042856A1 (en) * 1999-01-22 2000-07-27 The Schepens Eye Research Institute, Inc. Activation of regulatory t cells by alpha-melanocyte stimulating hormone
WO2002006316A2 (en) * 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CATANIA ANNA ET AL: "The neuropeptide alpha-melanocyte-stimulating hormone: A key component of neuroimmunomodulation", NEUROIMMUNOMODULATION, vol. 1, no. 2, 1994, pages 93 - 99, XP009028112, ISSN: 1021-7401 *
CUTULI M ET AL: "ANTIMICROBIAL EFFECTS OF ALPHA-MSH PEPTIDES", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 67, February 2000 (2000-02-01), pages 233 - 239, XP002931058, ISSN: 0741-5400 *
DELGADO HERNANDEZ RENE ET AL: "Inhibition of systemic inflammation by central action of the neuropeptide alpha-melanocyte-stimulating hormone", NEUROIMMUNOMODULATION, vol. 6, no. 3, May 1999 (1999-05-01), pages 187 - 192, XP009028113, ISSN: 1021-7401 *
HILTZ M E ET AL: "ANTI-INFLAMMATORY ACTIVITY OF ALPHA-MSH(11-13) ANALOGS: INFLUENCES OF ALTERATION IN STEREOCHEMISTRY", PEPTIDES, ELMSFORD, US, vol. 12, 1991, pages 767 - 771, XP000570459, ISSN: 0196-9781 *
See also references of WO0182699A1 *

Also Published As

Publication number Publication date
JP2004509065A (ja) 2004-03-25
CA2406755A1 (en) 2001-11-08
AU2001257420A1 (en) 2001-11-12
EP1280409A1 (en) 2003-02-05
WO2001082699A1 (en) 2001-11-08
CN1429073A (zh) 2003-07-09

Similar Documents

Publication Publication Date Title
GB0208759D0 (en) Transaction system and method therefor
AU2909001A (en) Sensor validation method and apparatus
GB0022444D0 (en) Positioning system and method
AU6271401A (en) Drug administering system and administering method
GB0028079D0 (en) System and method
AU2001265279A1 (en) Transactional supply chain system and method
EP1181073A4 (en) SYSTEM AND METHOD FOR VESTICULAR STIMULATION
IL134741A0 (en) Mobile transaction system and method
AU2001259013A1 (en) Transaction system and method
GB0111141D0 (en) Teleconferencing system and method
IL135821A0 (en) Manufacturing system and method
SG114516A1 (en) Data delivery method and data delivery system
SG102649A1 (en) Data delivery method and data delivery system
GB0104052D0 (en) Da`a mining method and system
AU1539501A (en) Transaction system and method
AU2701801A (en) Method and system for measuring heart rate variability
GB2363889B (en) Payment method and system
SG92765A1 (en) Dubbing system and dubbing method
GB2366897B (en) Electonic purchasing system and method
EP1280409A4 (en) A GENTHERAPY SYSTEM AND METHOD USING ALPHA-MSH AND ITS DERIVATIVES
GB0019500D0 (en) System and method
AU1457302A (en) Verification system and method
GB0005714D0 (en) Transaction system and method
AU2001280462A1 (en) Method and system for facilitating drug development
EP1222547A4 (en) PAYMENT SYSTEM AND METHOD

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021128

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040402

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/87 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 12N 15/74 B

Ipc: 7C 12N 15/09 B

Ipc: 7C 12N 15/00 B

Ipc: 7A 61K 31/70 B

Ipc: 7A 01N 43/04 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040827